Sleep at High Altitude-Nussbaumer-Ochsner et al
INTRODUCTION
Sleep at altitude is often perceived as disturbed and unrefreshing. 1, 2 Moreover, staying and sleeping at altitude is associated with the risk of developing high altitude illnesses 3 including acute mountain sickness (AMS), which is typically associated with insomnia and high altitude pulmonary edema (HAPE) causing cough and breathlessness. Data from several studies suggest that acute exposure to hypoxia alters sleep architecture by frequent awakenings and a reduction of deep sleep. [4] [5] [6] [7] [8] [9] The conclusions from these data are hampered by the small sample size and variations in the study setting (i.e., hypobaric chamber vs. field studies), ascent rate, and sleeping altitude. Whether changes in sleep persist during a stay at altitude over a few days remained uncertain.
Periodic breathing, an oscillatory pattern of waxing and waning of ventilation with periods of hyperventilation alternating with central apnea or hypopnea is often observed during sleep at altitude. [10] [11] [12] Whether it is the main cause of arousals and fragmented sleep at altitude is controversial, since arousals without a clear temporal relation to periodic breathing cycles have been described. 13 Lake Louise total score > 4 was considered to indicate acute mountain sickness. The question on insomnia within the Lake Louise questionnaire is reported separately.
EFFECT OF SHORT-TERM ACCLIMATIZATION TO HIGH ALTITUDE ON SLEEP

Data Analysis
Data are summarized as medians and quartiles. The effects of altitude and of acclimatization were evaluated by Wilcoxon matched pairs tests. A probability of P < 0.05 was considered significant.
RESULTS
Subjects
Twenty subjects were recruited. Three subjects withdrew after the baseline examination at Zurich, and one could not participate in polysomnography at 4559 m because of severe AMS. Therefore, data from 16 subjects (13 men, 3 women) were available for analysis. Median age was 45 (quartile range 33 to 50) years, the body mass index was 23.8 (23.1 to 25.2) kg/m. 2 Five subjects suffered from severe AMS on the second day at 4559 m and received dexamethasone, 4 mg twice daily.
Sleep Studies
A total of 47 polysomnographic recordings could be analyzed; one recording was lost because of technical failure.
Baseline studies at 490 m revealed normal sleep, breathing patterns, and oxygen saturation (Table 1) . On the first night at 4559 m, oxygen saturation was decreased, and a periodic breathing pattern with frequent central apneas/hypopneas was observed, predominantly in NREM sleep (Table 1, Figure 1 ). Minute ventilation had increased to almost one and a half of the value at 490 m, due to an increase in both tidal volume and breath rate. End-expiratory PCO 2 , a surrogate of arterial PCO 2 , was decreased (Table 1) . Sleep analysis during the first night at 4559 m revealed major changes in the hypnograms ( Figure  1 ). There were reductions in total sleep time, sleep efficiency, and slow wave sleep, while the total arousal index increased, although not in proportion to the number of apneas/hypopneas (Table 1, Figure 2 ).
Repeated recordings obtained in the third night at altitude revealed a partial improvement of mean oxygen saturation (SpO 2 ), associated with an increase in total sleep time, slow wave sleep, and REM sleep, and a reduction in the arousal index. However, the AHI increased further compared to the first night. Multiple regression analysis with percent slow wave sleep as the dependent variable and SpO 2 and the AHI as the independent variables revealed a significant positive effect of SpO 2 on slow wave sleep (β 0.38, P = 0.01) even after controlling for the AHI, while the negative association of the AHI and slow wave sleep did not quite reach statistical significance (β −0.26, P = 0.09). A separate analysis of data from the 5 subjects treated with dexamethasone on day 2 at 4559 m due to severe AMS revealed a major increase in oxygen saturation of 10% (quartile range 8,10) from 68% (67,69) in night 1 to 78% (76,81) in night 3 at 4559 m (P < 0.05). This increase significantly exceeded the corresponding increase of 3% (1,7) from 67% (64,70) in night 1 to 70% (68,71) in night 3 in the 11 subjects not receiving dexamethasone (P < 0.05). No change from night 1 to night 3 in any other variable listed in Tables 1 cended to Passo Salati (2971 m) by cable car and walked to the Gnifetti hut (3610 m) within 2-3 h to spend the night there. The following morning, subjects climbed to the Regina Margherita hut (4559 m) within 4-6 h and stayed there for 4 nights. Polysomnographies were performed during one night in Zurich and during the first and the third night at 4559 m from approximately 22:00 to 06:00. Subjects were not allowed to take any prophylactic medication, but were treated with dexamethasone tablets 4 mg twice daily if they suffered from severe AMS (Lake Louise score > 4).
Measurements
Polysomnography
Polysomnography was performed with a portable, battery powered device (LifeShirt, VivoMetrics, Ventura, CA, USA). 10, 17, 18 Derivations included a central electroencephalogram (EEG) (C3A2), electrooculogram (EOG) and submental electromyogram (EMG) leads, pulse oximetry, calibrated respiratory inductive plethysmography, and capnography of expired air. Relative gains of rib cage and abdominal inductance signals were determined in the evening by the qualitative diagnostic calibration procedure, 19 and their sum was calibrated in absolute units (L) by rebreathing into a bag of known volume (0.8 L) during several breaths. 10 Volume calibration was validated in the morning at the end of sleep studies and revealed that tidal volume estimates were within 20% of calibrated values.
Sleep stages and arousals were scored according to standard criteria. 20 Apneas/hypopneas were defined as previously described. 10 Briefly, a reduction of the inductive plethysmographic sum volume signal to < 50% of the preceding 2 min baseline during ≥ 10 s or during 5-10 s was scored as apnea/hypopnea if it occurred as part of a periodic breathing pattern. Central apneas/hypopneas were distinguished from obstructive apneas/ hypopneas by the absence of rib cage-abdominal asynchrony or paradoxical motion. The apnea/hypopnea index (AHI) was computed as the mean number of events per hour of sleep. The oxygen saturation measured by pulse oximetry was quantified in terms of the mean value during sleep (SpO 2 ), and the oxygen desaturation index (> 3% dips) expressed as events per hour of time in bed, since periodic breathing occurs during sleep as well as during wakefulness and to allow comparison to previous studies not using EEG.
Questionnaire and clinical examination
Subjective sleep quality was evaluated by visual analogue scales according to the Leeds questionnaire. 21, 22 For each question listed below, a vertical mark had to be placed on a line 100 mm in length. If no change was experienced compared to the usual sleep, the mark had to be placed in the center (at 50 mm). Perceived changes were represented by the distance of the mark from the center, with values < 50 mm (left of center) indicating worse and > 50 mm (right of center) indicating better. The following statements were rated: "Sleep was more restlessness than usual/more restful than usual." "There were more periods of wakefulness than usual/fewer periods of wakefulness than usual." "How did you feel on waking (tired/alert)".
Symptoms of acute mountain sickness were assessed by the Lake Louise protocol self-report and clinical assessment. 23 A
DISCUSSION
Our study is the first to provide comprehensive physiologic data including neurophysiologic and cardiorespiratory variand 2 significantly differed between the 5 subjects receiving dexamethasone and the 11 subjects not receiving dexamethasone (data not shown).
Symptoms and Clinical Examination
On the morning after the first night at altitude, the Lake Louise Score indicated that subjects suffered from symptoms of AMS and impaired sleep quality, with a greater degree of perceived nocturnal wakefulness and restlessness (Table 2) . These symptoms were partially relieved in the morning after the third night at 4559 m; the changes did not differ between the 5 subjects receiving dexamethasone and the remaining 11 subjects (data not shown). studies in 12 subjects on day 4 and 24 at 4800 m. Six subjects were randomized to loprazolam and 6 to placebo. In the placebo group, acclimatization resulted in an increase of total sleep time and the percentage of NREM stage 3 and REM sleep. No data immediately after arrival was recorded. Zielinski et al. 15 found no change in sleep variables in 9 subjects studied at 760 m and in the 1 st and 6 th night after arrival and stay at 3200 m. Correspondingly, Salvaggio et al. 16 did not find any changes in sleep variables with acclimatization from day 8 to day 28 at 5050 m in 5 subjects.
In the current study, short-term acclimatization over 3 days at 4559 m resulted in a partial recovery of sleep structure with increases in slow wave sleep, REM sleep and a reduction in the arousal index. During the same period, the amount of periodic breathing persisted. These finding are consistent with our previous observations in climbers acclimatizing at 4433 m and 5530 m. 10 Multiple regression analysis of data from the current study further revealed a positive effect of oxygen saturation on slow wave sleep at altitude after controlling for the AHI which is consistent with the hypothesis that acclimatization improved sleep quality via an independent effect on oxygen saturation despite a further increase in the AHI. The opposite trends of changes in the (increasing) apnea/hypopnea index and in the (decreasing) arousal index during acclimatization suggest that periodic breathing was not the predominant cause of sleep fragmentation at high altitude. Correspondingly, only a minor fraction of the apneas/hypopneas that occurred as part of high altitude periodic breathing was followed by an arousal (Figure 2) , which is in line with previous observations. 9, 13 Consistent with a hypoxic stimulation of ventilation, we found an increase in minute ventilation and a decrease in Pet-CO 2 in the first night at 4559 m. A high sensitivity to CO 2 and hypoxia along with a reduced CO 2 reserve are thought to be major determinants of periodic breathing. Thus, the increase in the apnea/hypopnea index in night 3 compared to night 1 at 4559 m despite a lesser degree of hypoxemia might be related to an increase in ventilatory drive induced by acclimatization.
Objective alterations in sleep structure and breathing instability at altitude were associated with subjective feelings of insomnia, nocturnal wakefulness, restless sleep and symptoms of AMS (Table 2) . AMS may have contributed to the sleep disturbances in the first night at 4559 m and the improvements in slow wave sleep, REM sleep, sleep fragmentation and subjective sleep disturbances in parallel with reductions of the AMS score additionally supports an interaction between AMS and sleep quality. On day 2 at 4559 m, 5 of the 16 subjects were treated with dexamethasone for major symptoms of AMS. These subjects experienced a rapid relief of AMS symptoms and an increase in SpO 2 . Dexamethasone might therefore have influenced their sleep and breathing in night 3 to some extent either directly or by improving AMS and promoting acclimatization. The fact that similar trends of changes in objective sleep variables and improvements in subjective sleep quality and AMS were also observed in the majority of subjects not receiving dexamethasone underlines the independent effects of acclimatization.
In summary, our study in a relatively large group of healthy subjects provides new insights into the effects of high altitude ables along with subjectively perceived sleep quality and symptoms of AMS during short-term acclimatization to high altitude. Altitude induced hypoxemia during the first night at 4559 m which was associated with a reduction in total sleep time, slow wave sleep, and REM sleep, and an increased number of arousals. Breathing patterns were characterized by increased minute ventilation and frequent central apneas/hypopneas. Three days of acclimatization resulted in partial improvements of oxygen saturation and of alterations in sleep architecture in the third night at 4559 m despite a further increase in apneas/hypopneas, suggesting that periodic breathing was not the predominant cause of sleep disturbances at altitude. Symptoms of AMS and subjective sleep disturbances were prominent after arrival at 4559 m but improved significantly with acclimatization.
The few previous studies that assessed the effect of acute hypobaric hypoxia on sleep and breathing disturbances are difficult to compare because of different study settings (field versus hypobaric chamber studies), differences in ascent rates, modes of transportation (cable car versus climbing), and sleeping altitudes. 5, 6, 8, 9, 24 Our field study performed in a relatively large number of subjects provides novel insights since it was performed in a realistic setting, i.e., study participants carried their own equipment, and the climbing rate and route were similar to that during recreational mountaineering in the Alps. Our results extend findings from some earlier hypobaric chamber studies suggesting a greater amount of superficial and fragmented sleep at a simulated altitude of 4000 m compared to sea level. 7, 8 In 12 soldiers pre-acclimatized to 1000 m, polysomnography performed in a mountain facility in the night after arrival at 3613 m revealed reductions in slow wave sleep and sleep efficiency but no change in REM sleep, and an increase in arousals compared to baseline studies at 1000 m. 6 In 14 trekkers ascending from 1400 to 5000 m in Nepal over the course of 12 days, slow wave sleep and sleep efficiency were reduced at some but not all altitudes. 9 Since this study comprised a prolonged exposure to increasing altitudes the effects of hypoxia and of acclimatization could not be separately assessed and compared to data from the current and the other cited studies.
The effects of altitude acclimatization on sleep have not been conclusively studied. Goldenberg et al.
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